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1. Introduction 
Cloacin DF13 is a bacteriocin produced by 
Enterobacter cloacae DF13 [l] . Treatment of 
sensitive bacteria with cloacin DFl3 results in leakage 
of potassium ions and inactivation of ribosomes 
[2]. This inactivation occurs both in vivo and in 
vitro and is accompanied by a specific cleavage of 16s 
rRNA near its 3’-terminus, producing a RNA frag- 
ment of 48 nucleotides [3]. In vitro inactivation of 
ribosomes i  only observed if purified preparations of
cloacin DF13 are used. Cell-free extracts prepared 
from cloacinogenic cells inhibit the in vitro activity 
of purified cloacin, although ribosomes i olated 
from sensitive as well as bacteriocin-producing 
cells are susceptible to the bacteriocin. These 
results uggest the presence of an inhibitor of 
cloacin DF13-action in cloacinogenic cells and are 
consistent with the observation that bacteriocinogenic 
cells are not susceptible to their homologous 
bacteriocin in vivo [4]. The specific immunity of 
cells harbouring abacteriocinogenic factor is 
believed to be caused by the production of an 
immunity substance which prevents the 
inactivation of ribosomes [ 5, 61. 
In this communication we describe the 
purification and characterization of the cloacin 
DF13 immunity protein from cloacinogenic cells. 
2. Materials and methods 
Cloacin DF13 was obtained from Enterobucter 
North-Holland Publishing Company - Amsterdam 
cloucae DF13 by induction with mitomycin C and 
purified by precipitation with ammonium sulphate and 
chromatography on QAE-Sephadex [7]. 
The sensitive strain Ent. cloacae Bz was used for 
determination of in vivo activity of cloacin DF 13 
111. 
Cloacin DF13 immunity protein was isolated 
from the cloacinogenic strain E. coli P678-54 
(Clo DFl3-Rep 3) obtained from A. J. Kool [8]. 
This strain possesses a three-fold increased number 
of Clo DF 13 plasmids compared to the wild type 
Ent. cloacae DF13. 
Cell-free extracts (S-30) were prepared from 
E. coli MRE 600 [2] . 
Immunity activity was assayed in a cell-free 
poly U-directed polyphenylalanine synthesizing system 
[2]. Aliquots of fractions to be tested were mixed with 
10 Asee units S-30 extract in TMK-buffer (0.01 M 
Tris-HCl pH 7.8,O.Ol M magnesium acetate and 
0.06 M KCl), 80 ~.tl reaction mixture [2] and 5 c(g 
purified cloacin DF13. After 15 min of preincuba- 
tion at 37°C 20 E.cg poly U and 0.5 &i ["Cl pheny 
lalanine (477 mCi/mmole) were added and the 
mixture was incubated for another 20 min at 37°C. 
The reaction was stopped by addition of 3 ml 5% 
trichloroacetic acid and the amount of 
polyphenylalanine synthesis was assayed [2]. 
3. Results 
For the isolation of immunity protein a 10 litre 
culture of E. coli P 678-54 (Clo DF13-Rep 3) in 
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Fig 1. Column chromatography of dialysed NaCl extracts The extract was applied to a column (2.5 X 45 cm) of 
DEAEXephadex A50 equilibrated in TMK-buffer and was washed into the column with 75 ml of the same buffer. The banded 
proteins were then eluted from the column with a 600 ml linear gradient of 0.0 to 1.0 M NaCl in TMK-buffer during 
24 hr. Fractions of 9 ml were collected, Fractions above the bracket contain maximum immunity activity. The arrow indicates 
the void volume of the column (o-o-e) absorbance at 280 nm; (-----) NaCl-gradient. 
Brain Heart Infusion (Oxoid) was grown in a 
MicroFerm laboratory fermentor (New Brunswick 
Scientific Co.) to a density of 5 X 10’ cells per ml and 
then induced for 60 min with 0.5 mg per liter of 
mitomycin C (Sigma). The cells were harvested by 
centrifugation and washed with saline. The cell pellet 
was then lysed by freezing and thawing twice. After 
addition of 1 mg DNase the broken cells were 
extracted for 20 min with 50 ml 1 M NaCl in 
TMK-buffer. The extraction was done at 0°C and 
repeated twice. The pooled extracts (150 ml) contain 
950 mg protein including cloacin DF13 and immunity 
substance. After overnight dialysis against 
TMK-buffer the immunity protein was separated from 
the bacteriocin and most of the other material by 
chromatography on a column of DEAESephadex 
(fig. 1). Eluted fractions were monitored for 
absorbance at 280 nm, in vivo cloacin activity and in 
vitro immunity activity. All cloacin activity 
elutes virtually in the void volume of the column. The 
immunity activity binds tightly to the 
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DEAE-Sephadex and was eluted between 0.6 and 0.7 
M NaCl . Fractions containing maximum immunity 
activity were pooled and concentrated by ammonium 
sulphate precipitation at 100% saturation. The 
pellet (56 mg protein) was dissolved in 3 ml 
TMK-buffer and dialysed against the same buffer. The 
concentrated preparation was further purified by 
gel-filtration on Sephadex G75 in TMK-buffer 
(fig. 2). The major peak eluted from this column 
contains much tRNA, the minor peak contains all the 
immunity activity. Fractions containing maximum 
activity were pooled and used without further 
concentration. The final yield of this purification 
was 24 mg purified immunity protein. 
Purified immunity protein runs as a single band on 
1% polyacrylamide gels in the presence of 0.1% 
sodium dodecyl sulphate (results not shown). For 
determination of the isoelectric point, a sample of 
purified immunity protein was subjected to 
isoelectric focusing in a density gradient-stabilized 
natural pH gradient as described by Vesterberg and 
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Fig. 2. Gel-fdtration of immunity protein, The concentrated 
preparation from the DEAE-Sephadex column was applied to 
a column (1 X 60 cm) of Sephadex G75 equihbrated in 
TMK-buffer. The column was eluted with the same buffer 
and 5 ml fractions were collected Fractions under the 
bracket contain maximum immunity activity. (e-o-o) 
Absorbance at 280 nm. 
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Fig 3. Isoelectric density gradient electrophoresis of purified 
immunity protein. Electrophoresis of 4.5 mg protein was 
performed in a pH 3 to 6 ampholyte preparation 
(Ampholine, LKB). Electrophoresis was continued for 
72 hr. Fractions of 30 drops were collected and 
monitored for absorbance at 280 nm and PH. 
( -) Absorbance at 280 nm; (o-e-e) pH gradient. 
Svensson [9]. As shown in fig. 3 the immunity pro- 
tein was banded as a single peak with an isoelectric 
point of 4.30. The sedimentation coefficient of 
purified immunity protein was determined by 
sedimentation velocity experiments in an analytical 
ultracentrifuge (Beckman-Spinco, model E). The 
preparation appears to be homogeneous and the 
Soze, w could be calculated as 1.7 S. Molecular 
weight analysis was performed by the sedimentation 
equilibrium method described by Schachman and 
Edelstein [lo] in an analytical ultracentrifuge 
equipped with a photoelectric scanner and using 
the multichannel short column equilibrium centers- 
piece SP 350.024. The analysis was performed by 
Dr. J. van ‘t Riet with three different concentrations 
of immunity protein in TMK-buffer at 24.630 rpm 
and 0°C. The molecular weight as determined by this 
technique is 10 500 assuming a partial specific 
volume of 0.725 ml per g. Chemical analysis of 
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Fig. 4. Titration of purified immunity protein against 
cloacin DF 13. Various amounts of purified immunity protein 
were added to in vitro protein synthesizing systems con- 
taming 5 pg purified cloacin DF13 (o-o-o) titration curve 
with cloacin; (o-o-o) control experiment without cloacm. 
100% Synthesis in control experiments tands for the 
incorporation of 2 nmole [ t4C] phenylalanine into 
polyphenylalanme. In the presence of 5 pg purified 
cloacin DF13 this incorporation is reduced to 0.45 nmole 
[ t4C] phenylalanine. 
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purified immunity protein showed that the 
preparation contained no detectable amount of 
nucleic acid or carbohydrate. 
The potency of purified immunity protein to 
neutralize the in vitro activity of purified cloacin 
DF13 was determined by adding various amounts of 
immunity protein to assay systems containing a
given amount of cloacin (fig. 4). From this 
titration it could be calculated that the neutralization 
of one c(g clacin DF 13 requires no more than one 
peg immunity protein. 
If a mixture of purified cloacin and immunity pro- 
tein was added to exponentially growing cells of 
sensitive bacteria the immunity protein could not 
prevent he lethal action of the cloacin even in a 
lOO-fold excess (table 1). 
Table 1 
Effect of purified immunity protein on the killing action of 
cloacin DF13 in vivo 
Cloacin 
@g) 
Immunity 
protein 
(ccg) 
% surviving 
cells 
0 0 100 
5 0 2 
5 500 2 
8 X 10’ Exponentially growing cells of Enterobacter cloacae 
02 were mixed with 500 c(g purified immunity protein and/or 
5 tig purified cloacin DFI 3. After incubation for 20 min at 
37’C the mixtures were dihtted and spreaded on broth-agar 
plates. After overnight incubation at 37°C the surviving 
colonies were scored 
No immunity protein could be detected if a 
parallel purification was carried out on an extract of 
E. coli P678-54 which means that the immunity 
protein is specific for cells harbouring the 
cloacinogenic factor. 
4. Ditmssion 
Bacterial cells harbouring the cloacinogenic factor 
DF13 appear to produce a small acidic protein which 
completely blocks the in vitro inactivation of 
ribosomes by cloacin DF13. However, this so-called 
immunity protein cannot protect sensitive cells from 
being killed in vivo by the bacteriocin. Obviously the 
immunity protein cannot penetrate into sensitive cells 
nor prevent he effective adsorbtion of bacteriocin 
molecules to the specific cell envelope receptors. 
Therefore the immunity protein is only active in the 
cytoplasm of bacteriocin producing cells or in in 
vitro systems. From these results two possibilities 
might be predicted with respect o its mechanism 
of action. Either the immunity protein interacts 
directly with the bacteriocin or it protects the 
ribosomes from inactivation. Binding of immunity 
protein with bacteriocin might neutralize the affinity 
of the bacteriocin molecules to the ribosomes without 
any effect on their affinity to the cell surface 
receptors. Binding of immunity protein to the 
ribosomes hould allow protein synthesis while 
preventing the cleavage of 16 S rRNA by cloacin 
DF13. 
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